| Company History |
2011
► TaiwanJ was incorporated.
2013
► TFDA approved to proceed JKB-122 HCV Phase II trial.
2014
► Ministry of Economic Affairs approved "high-quality case accelerate plan" primary selection.
2015
► TaiwanJ relocated to Hsinchu Biomedical Science Park.
► FDA approved to proceed JKB-121 NASH Phase II trial in US TFDA approved to proceed JKB-122 NAFLD Phase II trial.
► TaiwanJ passed public company qualification, stock code 6549.
► TFDA approved to proceed JKB-122 AIH Phase II trial.
► TaiwanJ was approved by the Ministry of Economy as a "new drugs biotech company".
► FDA granted orphan drug designation for using JKB-122 to treat AIH.
► TaiwanJ registered as an emerging company in Taipei Exchange.
2016
► TaiwanJ was awarded the 13th National Innovation Award for "First-In-Class Drug for Chronic Liver Disease" in the Pharmaceutical and New Medical Technology Category by the Institute for Biotechnology and Medicine Industry.
2017
► Published an autoimmune hepatitis (AIH) article for JKB-122 in European Journal of Pharmacology.
2018
► Reached the primary endpoint and partial secondary endpoints with significant effects for JKB-122 in the Phase 2 clinical trial on Non-Alcoholic Fatty Liver Disease (NAFLD).
2019
► Reached the primary endpoint and partial secondary endpoints with significant effects for JKB-122 in the Phase 2 clinical trial on Autoimmune Hepatitis (AIH).
► Signed the deal with Newsoara Biopharma for out-licensing the Asian rights of JKB-122 for upfront and milestone payments of US$26M in addition to the royalty payment after marketing the drug.
2020
► JKB-122 for nonalcoholic steatohepatitis (NASH) treatment was approved by the FDA for Phase 2 human clinical trials.
► The new dosage form of KB-122 was approved by the Taiwan and the United States FDA for clinical trials.
► The statistical results of the CDA-HFD animal test of TJC-265 (autotaxin inhibitor), TaiwanJ’s small molecule new drug, and FASN inhibitor, Merck Healthcare KGaA’s small molecule new drug combining use for non-alcoholic steatohepatitis (NASH)showed positive in both primary and secondary indicators.
► JKB-122 for newly diagnosed autoimmune hepatitis (AIH) was approved by FDA for Phase II human clinical trials.
2021
► TaiwanJ signed an exclusive licensing deal for the new drug Autotaxin Inhibitor TJC-265 with Newsoara Biopharma Co., Ltd. The upfront and milestones reach up to US$51.5 million, and the royalty rate will be up to double digits (3% to 10%).
► TaiwanJ was incorporated.
2013
► TFDA approved to proceed JKB-122 HCV Phase II trial.
2014
► Ministry of Economic Affairs approved "high-quality case accelerate plan" primary selection.
2015
► TaiwanJ relocated to Hsinchu Biomedical Science Park.
► FDA approved to proceed JKB-121 NASH Phase II trial in US TFDA approved to proceed JKB-122 NAFLD Phase II trial.
► TaiwanJ passed public company qualification, stock code 6549.
► TFDA approved to proceed JKB-122 AIH Phase II trial.
► TaiwanJ was approved by the Ministry of Economy as a "new drugs biotech company".
► FDA granted orphan drug designation for using JKB-122 to treat AIH.
► TaiwanJ registered as an emerging company in Taipei Exchange.
2016
► TaiwanJ was awarded the 13th National Innovation Award for "First-In-Class Drug for Chronic Liver Disease" in the Pharmaceutical and New Medical Technology Category by the Institute for Biotechnology and Medicine Industry.
2017
► Published an autoimmune hepatitis (AIH) article for JKB-122 in European Journal of Pharmacology.
2018
► Reached the primary endpoint and partial secondary endpoints with significant effects for JKB-122 in the Phase 2 clinical trial on Non-Alcoholic Fatty Liver Disease (NAFLD).
2019
► Reached the primary endpoint and partial secondary endpoints with significant effects for JKB-122 in the Phase 2 clinical trial on Autoimmune Hepatitis (AIH).
► Signed the deal with Newsoara Biopharma for out-licensing the Asian rights of JKB-122 for upfront and milestone payments of US$26M in addition to the royalty payment after marketing the drug.
2020
► JKB-122 for nonalcoholic steatohepatitis (NASH) treatment was approved by the FDA for Phase 2 human clinical trials.
► The new dosage form of KB-122 was approved by the Taiwan and the United States FDA for clinical trials.
► The statistical results of the CDA-HFD animal test of TJC-265 (autotaxin inhibitor), TaiwanJ’s small molecule new drug, and FASN inhibitor, Merck Healthcare KGaA’s small molecule new drug combining use for non-alcoholic steatohepatitis (NASH)showed positive in both primary and secondary indicators.
► JKB-122 for newly diagnosed autoimmune hepatitis (AIH) was approved by FDA for Phase II human clinical trials.
2021
► TaiwanJ signed an exclusive licensing deal for the new drug Autotaxin Inhibitor TJC-265 with Newsoara Biopharma Co., Ltd. The upfront and milestones reach up to US$51.5 million, and the royalty rate will be up to double digits (3% to 10%).